
IRIDEX (NASDAQ:IRIX) lowered its full-year revenue outlook after third-quarter sales fell short of expectations, as international distributors worked through inventory and regulatory delays and pricing pressure weighed on its retina business.
The medical technology company reported revenue of $10.2 million for the quarter ended October 3, 2026, down from $12.5 million a year earlier. It now expects full-year revenue of $46 million to $48 million, excluding the Middle East.
CEO Patrick Mercer said the results were disappointing, but pointed to higher gross margins and the completion of a manufacturing relocation as steps toward profitability. The company is reviewing its product portfolio and international distribution model, potentially accepting lower revenue in exchange for better margins and lower costs.
International Sales Weigh on Results
Retina product revenue declined to $5.1 million from $6.7 million a year earlier. Chief Financial Officer Romeo Dizon attributed the decrease to deferred shipments in Japan, weakness in China, registration delays in India and regulatory and competitive pressures in Europe.
Mercer said U.S. PASCAL revenue increased approximately 50% year over year. In Japan, a partner deferred shipments into the fourth quarter after building inventory ahead of the company’s relocation. That included an approximately $300,000 order IRIDEX expects to ship in the fourth quarter.
In Europe, the company continues to sell its existing PASCAL product, but some distributors are waiting for approval of the newer Iridex PASCAL system before placing orders, Mercer said. Management expects PASCAL medical device regulation approval in the first half of 2027.
Mercer also cited weakness in China during the question-and-answer session, saying the company had received about $400,000 in orders from the country this year, compared with $4 million last year.
Cyclo G6 product family revenue fell to $3.2 million from $3.5 million, as lower international sales offset higher U.S. probe prices and system revenue. Global G6 probe volume was approximately 11,900 units, compared with 14,900 a year earlier. U.S. probe volume was roughly flat at 6,900 units.
Mercer said he expects fourth-quarter probe sales and G6 system placements to increase sequentially and year over year. He cited the quarter’s typical seasonal strength and an expected recovery in international system orders.
Margins Improve as Cash Balance Falls
Gross margin rose to 42.4% from 32.1% in the prior-year quarter. The earlier period included a roughly $0.8 million inventory write-down; excluding that charge, the prior-year margin would have been 38.7%. Dizon said the improvement reflected a more favorable geographic mix and pricing discipline.
Operating expenses were $5.5 million, compared with $5.4 million a year earlier. Net loss narrowed to $1.4 million, or $0.08 per share, from $1.6 million, or $0.09 per share. Adjusted EBITDA loss widened to $0.6 million from $0.1 million.
Cash and cash equivalents stood at $3.7 million at quarter-end, down from $4.7 million at the end of the second quarter. Net cash used in operating activities was $1.0 million. Dizon cited lower revenue and a $1.6 million inventory increase as the company built safety stock for distributors during registration-related shipping interruptions.
Management expects cash use to decrease as inventory is sold and receivables are collected. In response to an analyst’s question, Dizon said the company could generate positive adjusted EBITDA for the fourth quarter if revenue reaches the higher end of the analyst’s implied $11.5 million to $13.5 million range. He said IRIDEX would not be adjusted EBITDA positive for the full year because of losses in the first three quarters.
Focus Turns to 2027 Profitability
IRIDEX completed its manufacturing move from Mountain View to San Jose on October 5. Mercer said the relocation is expected to save approximately $600,000 in annual rent. The company has completed TÜV and BSI audits and is awaiting final reports and certificates before initiating manufacturing for international markets at the new site.
Management also expects additional operating expense reductions and higher margins as major products transition to third-party contract manufacturers, a process it expects to complete in 2027. Mercer said the portfolio review will focus on more profitable products and markets.
IRIDEX maintained its 2026 adjusted operating expense outlook of $19 million to $19.5 million. Dizon said the company was not providing 2027 guidance.
About IRIDEX (NASDAQ:IRIX)
IRIDEX Corporation develops, manufactures and markets laser-based medical systems and related delivery devices for eye-care professionals. Its products are used to treat retinal diseases and glaucoma, including through laser procedures designed to preserve or improve vision. The company’s offerings include ophthalmic laser systems such as the Cyclo G6 glaucoma laser system and IQ-series photocoagulators, along with treatment-delivery devices and technologies including MicroPulse laser therapy. IRIDEX was founded in 1989 and serves customers internationally through direct sales and distribution partners.
